New Research Finds Potential Genetic Link between DR4 Allele and Reduced Risk of Parkinson’s and Alzheimer’s Disease
Stanford University Study Reveals Promising Insights
In a groundbreaking study conducted by a research team at Stanford University School of Medicine, it has been discovered that individuals possessing a specific allele known as DR4 are less susceptible to developing debilitating neurodegenerative diseases like Parkinson’s and Alzheimer’s.
By analyzing the extensive genetic database of over 100,000 Alzheimer’s disease patients and 40,000 Parkinson’s disease patients from diverse regions around the globe, researchers have unearthed compelling evidence demonstrating that one in five individuals possess the DR4 allele. Furthermore, it has been observed that DR4 gene carriers exhibit, on average, a 10% reduced risk of developing both Parkinson’s and Alzheimer’s disease.
Alleles are genes that exist in the same location but showcase different characteristics based on individual variation. Noteworthy examples include genes responsible for determining blood type or the color of peas.
A spokesperson from the research team stated, “DR4 was already known to play a role in safeguarding individuals against Parkinson’s disease; however, our findings unveil a similar protective effect against the onset of Alzheimer’s disease.” The spokesperson further elaborated, “Individuals possessing the DR4 allele may experience enhanced preventive benefits upon receiving vaccines targeting Alzheimer’s disease.”
Furthermore, the team meticulously analyzed brain data obtained from autopsies conducted on more than 7,000 patients who had tragically succumbed to Alzheimer’s disease. The findings indicated that individuals harboring the DR4 allele manifest considerably fewer neurofibrillary tangles, such as tau protein, which are known contributors to the progression of Alzheimer’s disease, in comparison to those lacking the DR4 allele.
Elucidating on this aspect, the research team spokesperson stated, “Administering vaccines to individuals with the presence of tau protein aggregates in the brain may effectively delay the onset of Alzheimer’s and Parkinson’s disease; however, it is imperative to conduct a blood test for determining the presence of the DR4 allele before making a decision.”
These groundbreaking findings present a potential avenue for the development of preventive measures and targeted therapies in managing and mitigating the devastating effects of neurodegenerative diseases. As researchers delve deeper into the intricate world of genetics, the path towards a disease-free future appears increasingly optimistic.
[박지윤 디지털뉴스부 인턴기자 bakjy7858@gmail.com]
Research has shown that people with a certain allele (DR4) are less likely to develop Parkinson’s disease as well as Alzheimer’s disease (dementia).
A research team at Stanford University School of Medicine in the US analyzed the genetic database of more than 100,000 Alzheimer’s disease patients and 40,000 Parkinson’s disease patients from around the world, and found that one in five people have a specific allele (DR4), and DR4 The risk of developing Parkinson’s disease and Alzheimer’s disease was found to be reduced by an average of 10%.
An allele is a gene that is located in the same location but has different characteristics depending on the person. Examples include genes that determine a person’s blood type or the color of a pea.
An official from the research team said, “DR4 was known to play a role in protecting the human body from Parkinson’s disease, and this time it was discovered that this effect is also expressed in Alzheimer’s disease.” He added, “If a DR4 holder receives a vaccine related to Alzheimer’s disease, “It seems that we will be able to enjoy a preventive effect much more than people,” he said.
In addition, the research team analyzed brain data from autopsies of more than 7,000 patients who died of Alzheimer’s disease. As a result, we found that people with DR4 develop much less neurofibrillary tangles, such as tau protein, which contributes to the worsening of Alzheimer’s disease, compared to people without DR4.
An official from the research team said, “If people who have started to accumulate tau protein aggregates in the brain receive the vaccine, the onset of Alzheimer’s disease and Parkinson’s disease can be delayed, but this only applies to people with DR4. ” That’s why you have to get a blood test before you decide if you should do it.”
[박지윤 디지털뉴스부 인턴기자 bakjy7858@gmail.com]
#People #allele #DR4 #develop #Parkinsons #disease #dementia
